Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection

Chunmei Yang; Mixue Xie; Kaifeng Zhang; Hui Liu; Aibin Liang; Ken H. Young; Wenbin Qian

doi:10.1038/s41375-020-0913-y

Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection

Chunmei Yang, Mixue Xie, Kaifeng Zhang, Hui Liu, Aibin Liang, Ken H. Young, Wenbin Qian

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	3055-3059
Number of pages	5
Journal	Leukemia
Volume	34
Issue number	11
DOIs	https://doi.org/10.1038/s41375-020-0913-y
State	Published - Nov 1 2020
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-020-0913-y

Cite this

@article{dd44e370ac2b4219a0265e0dc501c779,

title = "Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection",

author = "Chunmei Yang and Mixue Xie and Kaifeng Zhang and Hui Liu and Aibin Liang and Young, {Ken H.} and Wenbin Qian",

note = "Funding Information: Acknowledgements This study was supported by funds from the National Natural Science Foundation of China (No. 81830006, 81830004, 81670178), Science Technology Department of Zhejiang Province (No. 2018C03016-1), and the Natural Science Foundation of Zhejiang Province (No. LY20H080006, LY18H16008).",

year = "2020",

month = nov,

day = "1",

doi = "10.1038/s41375-020-0913-y",

language = "English (US)",

volume = "34",

pages = "3055--3059",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection

AU - Yang, Chunmei

AU - Xie, Mixue

AU - Zhang, Kaifeng

AU - Liu, Hui

AU - Liang, Aibin

AU - Young, Ken H.

AU - Qian, Wenbin

N1 - Funding Information: Acknowledgements This study was supported by funds from the National Natural Science Foundation of China (No. 81830006, 81830004, 81670178), Science Technology Department of Zhejiang Province (No. 2018C03016-1), and the Natural Science Foundation of Zhejiang Province (No. LY20H080006, LY18H16008).

PY - 2020/11/1

Y1 - 2020/11/1

UR - http://www.scopus.com/inward/record.url?scp=85086334680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086334680&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-0913-y

DO - 10.1038/s41375-020-0913-y

M3 - Article

C2 - 32533094

AN - SCOPUS:85086334680

SN - 0887-6924

VL - 34

SP - 3055

EP - 3059

JO - Leukemia

JF - Leukemia

IS - 11

ER -

Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this